Main > PNEUMOLOGY > Artificial Lung. > Catheter Implanted in Vena Cava. > Use: Poly(Propylene) Hollow-Fiber > MicroPorous Membrane > Development by

Product USA. A

BUSINESS INFORMATION As an early-stage company, it has raised $1.5 million from private angel investors and will soon occupy space outside of the institute. The next goal is to raise $8 million in venture financing, part of the $15 million needed to build and qualify the artificial lungs for Food & Drug Administration approval. Co is not generating revenues yet
TECHNOLOGY "Our goal is to supplement but not replace the lungs" of patients who have difficulty breathing. Co. developing an intravenous membrane oxygenator. artificial lung will free emphysema patients from uncomfortable mechanical ventilators when they need assistance breathing.

Instead, patients will be able to eat, talk, and move around while a temporary catheter, implanted into the vena cava and connected to a mobile unit, substitutes 40 to 60% of a patient's compromised lung capacity. Co says he is working now to reduce the size of the catheter, which uses microporous polypropylene hollow-fiber membranes to diffuse oxygen into the blood and pull out carbon dioxide.

UPDATE 11.02
COMPANY This data is not available for free
CONTACT This data is not available for free
LITERATURE REF. This data is not available for free

Want more information ?
Interested in the hidden information ?
Click here and do your request.


back